Data from the phase 2 DYNAMIC trial show that a circulating tumor DNA–guided approach to adjuvant therapy selection may be feasible for patients with stage II colorectal cancer, but Tanios S. Bekaii-Saab, MD, is skeptical about its readiness for prime time.
Paul G. Richardson, MD, presented data from the phase 3 DETERMINATION study at 2022 ASCO and theorized how these findings could extend to similar regimens in newly diagnosed multiple myeloma.
Focusing broadly on breast cancer, expert oncologists detail how ctDNA may impact patient monitoring and treatment decisions moving forward.
Moving on to the second patient scenario, panelists elucidate the value of ctDNA in patients with triple-negative breast cancer.
A brief discussion on the toxicities and drug-drug interactions associated with frontline therapies in metastatic CSPC and when it would be appropriate to alter treatment to mitigate toxicity.
Focused discussion on drug and patient factors that aid in the selection of frontline therapy for metastatic castration-sensitive prostate cancer.
Alexis A. Thompson, MD, MPH, spoke about the use of betibeglogene autotemcel for patients with β-thalassemia.
Rafael Fonseca, MD, describes key data from the MAIA and SWOG 0777 studies investigating triplet regimens in multiple myeloma treatment, and how the results compare.
Dr Luciano Costa provides an overview of the currently available treatment options for patients with transplant-ineligible, newly diagnosed multiple myeloma.
Hematologist/oncologists provide a broad overview of the pharmacologic agents used to prevent graft vs host disease at their institutions.
Expert panelists elucidate the occurrence of graft vs host disease in patients receiving either stem cell or allogeneic transplantation.
Data from the PARADIGM trial that were presented at 2022 ASCO demonstrated that panitumumab plus FOLFOX should be standard of care for patients with left-sided, RAS wild-type colorectal cancer, according to Tanios S. Bekaii-Saab, MD.
Valentina Boni, MD, PhD, spoke about numerous trials in the breast cancer space presented at 2022 ASCO.
Tanios S. Bekaii-Saab, MD, discussed how data from clinical trials examining different targeted strategies in colorectal cancer will transform the way in which patients with this malignancy are seen and treated.
Ian D. Davis, MBBS, PhD, spoke about the subgroup analysis of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.
The panel closes their discussion on myelofibrosis treatment updates by sharing clinical pearls for community oncologists.
Experts delve into the unmet needs in the myelofibrosis treatment landscape and highlight promising ongoing clinical trials.
At 2022 ASCO, Tanios S. Bekaii-Saab, MD, talks about how data from the ongoing MOUNTAINEER trial investigating trastuzumab plus tucatinib in HER2-positive metastatic colorectal cancer and other similar trials may impact the standard of care going forward.
Shared insight on the frontline use of chemotherapy options for patients with metastatic CSPC in the context of AR-targeted therapies.
After reviewing a patient scenario of metastatic castration-sensitive prostate cancer, expert panelists break down frontline treatment options in this setting.
In the context of clinical trial data and personal experience, experts weigh the value of circulating tumor DNA as a tool in cancer care.
Experts share their perspective on clinical trial data driving the use of circulating tumor DNA in various settings of cancer care.
Paul G. Richardson, MD, looks at MRD data from the DETERMINATION study for its potential to guide treatment selection in newly diagnosed multiple myeloma.
At the 2022 WCLC, Brandon Sheffield, MD, presented data demonstrating the advantage of next-generation sequencing over other biomarker testing strategies in patients with non–small cell lung cancer.
Data from a substudy of the phase 3 VISION trial presented at 2022 ASCO Annual Meeting showed that higher standard mean uptake value by PSMA-PET is strongly associated with outcomes for patients with metastatic castration-resistant prostate cancer.
Focusing on breast cancer, lung cancer, and GI cancers respectively, expert oncologists review the utility of circulating tumor DNA assays.
Expert panelists elucidate the mechanisms of ctDNA and MRD testing, providing a broad perspective on how they are used in cancer care.
At 2022 ASCO, Roy S. Herbst, MD, PhD, spoke about the results of a Lung-MAP substudy showing benefit of ramucirumab plus pembrolizumab vs standard of care chemotherapy for patients with advanced non–small cell lung cancer who demonstrated resistance to prior immunotherapy.
Thought leaders in breast oncology share closing remarks about the future management of HER2+ BC with brain metastases with key insights on unmet needs and evolving treatment approaches.
Expert panelists discuss insights on HER2+ BC from the 2022 ASCO Annual Meeting including safety updates from DESTINY-BREAST03, data on the potential prognostic value of TILs, and trials on local therapy for oligometastatic disease.
